Table 3

Number of subjects categorized according to time spent in remission divided by subject-specific follow-up duration, for each of the remission criteria tested

All subjects in BRASS with ≥2 years of follow-up


Time in remission (%)

DAS28-CRP < 2.6

N = 871a

DAS28-CRP < 2.3

N = 871a

SDAI

N = 871a

CDAI

N = 871a

ACR/EULAR

N = 871a


0

326 (37%)

401 (46%)

599 (69%)

610 (70%)

634 (73%)

1-25

130 (15%)

146 (17%)

94 (11%)

30 (3%)

87 (10%)

26-50

196 (23%)

163 (19%)

108 (12%)

127 (15%)

101 (12%)

51-75

121 (14%)

102 (12%)

52 (6%)

66 (8%)

39 (4%)

76-99

52 (6%)

30 (3%)

10 (1%)

17 (2%)

7 (1%)

100

46 (5%)

29 (3%)

8 (1%)

21 (2%)

3 (0.3%)


Overall mean time in remission

31%

24%

12%

15%

10%


Selected population of subjects in BRASS


Time in remission (%)

DAS28-CRP < 2.6

N = 309b

DAS28-CRP < 2.3

N = 275b

SDAI

N = 168b

CDAI

N = 170b

ACR/EULAR

N = 158b


1-25

77 (25%)

89 (32%)

58 (35%)

54 (32%)

60 (38%)

26-50

133 (43%)

111 (40%)

62 (37%)

72 (42%)

64 (41%)

51-75

49 (16%)

37 (13%)

30 (18%)

24 (14%)

18 (11%)

76-99

28 (9%)

21 (8%)

6 (4%)

7 (4%)

8 (5%)

100

22 (7%)

17 (6%)

12 (7%)

13 (8%)

8 (5%)


Overall mean

time in remission

48%

45%

44%

44%

42%


aSubjects in BRASS with ≥2 years of follow-up. Maximum number of visits is eight. bSubjects in BRASS with ≥2 years of follow-up, one or more visits in remission, according to the various

definitions; ≥1 year follow-up after first visit in remission and not in remission at entrance into

BRASS. Maximum number of visits is seven (because visit at entrance into BRASS is excluded).

Prince et al. Arthritis Research & Therapy 2012 14:R68   doi:10.1186/ar3785

Open Data